Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Huyang Yangkun granules is a Traditional Chinese Medicine (TCM) formulation developed by the Guangdong Provincial Hospital of Chinese Medicine. It is primarily indicated for the treatment of premature ovarian insufficiency (POI), a condition characterized by the loss of normal ovarian function before the age of 40. The formulation, particularly an 'Improved Formula,' is being evaluated in clinical trials for its ability to promote the recovery of residual ovarian follicles and improve fertility outcomes in women with POI. As a modern TCM preparation, it is administered in granule form and consists of a standardized mixture of herbal extracts intended to regulate reproductive endocrine function and improve the ovarian microenvironment.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Huyang Yangkun granules.